ArticleGynecologic oncology2013

A phase I clinical trial of Ad5/3-Δ24, a novel serotype-chimeric, infectivity-enhanced, conditionally-replicative adenovirus (CRAd), in patients with recurrent ovarian cancer.

Kenneth H Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.